Last-Chance treatment offered for Tough-to-Treat blood cancer
NCT ID NCT05503550
Summary
This program provided early access to an investigational drug called talquetamab for patients with multiple myeloma that had stopped responding to standard treatments. It was designed for doctors to request the drug for individual patients who had exhausted other options. The program is now closed and no longer accepting requests.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.